Literature DB >> 9662356

Genetic testing and Alzheimer disease: has the time come? Alzheimer Disease Working Group of the Stanford Program in Genomics, Ethics & Society.

L M McConnell1, B A Koenig, H T Greely, T A Raffin.   

Abstract

Entities:  

Keywords:  Alzheimer Working Group of the Stanford Program in Genomics, Ethics and Society; Genetics and Reproduction; Mental Health Therapies

Mesh：

Substances：

Year:  1998        PMID： 9662356     DOI： 10.1038/nm0798-757

Source DB:  PubMed          Journal:  Nat Med        ISSN： 1078-8956            Impact factor:   53.440


× No keyword cloud information.
  9 in total

Review 1.  Ethical, legal, and social dimensions of epilepsy genetics.

Authors:  Sara Shostak; Ruth Ottman
Journal:  Epilepsia       Date:  2006-10       Impact factor: 5.864

2.  Differences between African American and White research volunteers in their attitudes, beliefs and knowledge regarding genetic testing for Alzheimer's disease.

Authors:  Ibidapo Akinleye; J Scott Roberts; Charmaine D M Royal; Erin Linnenbringer; Thomas O Obisesan; Grace-Ann Fasaye; Robert C Green
Journal:  J Genet Couns       Date:  2011-06-09       Impact factor: 2.537

3.  Estimating and disclosing the risk of developing Alzheimer's disease: challenges, controversies and future directions.

Authors:  J Scott Roberts; Sarah M Tersegno
Journal:  Future Neurol       Date:  2010-07-01

Review 4.  Using Alzheimer's disease as a model for genetic risk disclosure: implications for personal genomics.

Authors:  J S Roberts; K D Christensen; R C Green
Journal:  Clin Genet       Date:  2011-07-18       Impact factor: 4.438

5.  Disclosure of APOE genotype for risk of Alzheimer's disease.

Authors:  Robert C Green; J Scott Roberts; L Adrienne Cupples; Norman R Relkin; Peter J Whitehouse; Tamsen Brown; Susan LaRusse Eckert; Melissa Butson; A Dessa Sadovnick; Kimberly A Quaid; Clara Chen; Robert Cook-Deegan; Lindsay A Farrer
Journal:  N Engl J Med       Date:  2009-07-16       Impact factor: 91.245

6.  Comparing test-specific distress of susceptibility versus deterministic genetic testing for Alzheimer's disease.

Authors:  Michael R Cassidy; J Scott Roberts; Thomas D Bird; Ellen J Steinbart; L Adrienne Cupples; Clara A Chen; Erin Linnenbringer; Robert C Green
Journal:  Alzheimers Dement       Date:  2008-11       Impact factor: 21.566

7.  Impact of gene patents and licensing practices on access to genetic testing for Alzheimer disease.

Authors:  Katie Skeehan; Christopher Heaney; Robert Cook-Deegan
Journal:  Genet Med       Date:  2010-04       Impact factor: 8.822

8.  Genetic counseling and testing for Alzheimer disease: joint practice guidelines of the American College of Medical Genetics and the National Society of Genetic Counselors.

Authors:  Jill S Goldman; Susan E Hahn; Jennifer Williamson Catania; Susan LaRusse-Eckert; Melissa Barber Butson; Malia Rumbaugh; Michelle N Strecker; J Scott Roberts; Wylie Burke; Richard Mayeux; Thomas Bird
Journal:  Genet Med       Date:  2011-06       Impact factor: 8.822

9.  Alzheimer's disease care and management: role of information technology.

Authors:  Hanuman Thota; Allam Appa Rao; Kiran Kumar Reddi; Sivaprasad Akula; Suresh Babu Changalasetty; Gedela Srinubabu
Journal:  Bioinformation       Date:  2007-11-03
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.